Genmab Enters Strategic Partnership with Immatics to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
327
Genmab Enters Strategic Partnership with Immatics to Discover and Develop Next Generation Bispecific Cancer Immunotherapies

Company Announcement

  • Genmab gains exclusive access to multiple novel proprietary tumor targets identified by Immatics Biotechnologies’ XPRESIDENT ® technology
  • Creation of novel immuno-oncology drugs combining Genmab and Immatics’ proprietary technologies
  • Genmab responsible for development, manufacturing and commercialization worldwide
  • Immatics to receive upfront payment of USD 54 million from Genmab

Copenhagen, Denmark; July 12, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that it has entered into a research collaboration and exclusive license agreement with privately owned Immatics Biotechnologies GmbH (Immatics), to discover and develop next-generation bispecific immunotherapies to target multiple cancer indications. The deal strengthens Genmab’s position in immuno-oncology by combining Genmab's proprietary technologies and antibody know-how with Immatics' XPRESIDENT ® targets and T-cell receptor (TCR) capabilities.  Genmab will receive an exclusive license to three proprietary targets from Immatics, with an option to license up to two additional targets at predetermined economics. The companies will conduct joint research, funded by Genmab, on multiple antibody and/or TCR-based bispecific therapeutic product concepts.

Genmab may elect to progress any resulting product candidates, and will be responsible for development, manufacturing and worldwide commercialization. For any products that are commercialized by Genmab, Immatics will have an option to limited co-promotion efforts in selected countries in the EU.

“This collaboration with Immatics gives us the opportunity to combine our unique technologies and expertise to create differentiated novel next-generation therapies. We very much look forward to this exciting partnership in the field of cancer immunotherapy,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Carsten Reinhardt, M.D., Ph.D., Chief Medical Officer and Managing Director of Immatics, commented: “We are very pleased to join forces with one of the world-leading biotechnology companies to develop and advance novel and highly active cancer therapeutics. This collaboration underpins Immatics’ leadership in intracellular tumor target identification and T-cell receptor engineering.” Dr. Reinhardt further said: “Our bispecific TCR technology exhibits exceptional potency and favourable pharmacokinetic properties by combining Immatics’ proprietary T-cell engaging format with our high-affinity and highly specific T-cell receptors as reported at AACR 2018 1 .” Under the terms of the agreement, Genmab will pay Immatics an upfront fee of USD 54 million and Immatics is eligible to receive up to USD 550 million in development, regulatory and commercial milestone payments for each product, as well as tiered royalties on net sales.

Today’s news does not impact Genmab’s 2018 Financial Guidance.

About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX ® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra ® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody ® platform for generation of bispecific antibodies, and the HexaBody ® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com . About Immatics Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The Company’s transformative product candidates are ‒ best in class ‒ Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics’ proprietary and world-leading XPRESIDENT ® technology. XPRESIDENT ® is the most sensitive, unbiased and high-throughput technology capable of identifying targets in virtually any type of cancer and any HLA type. Together with Immatics’ powerful TCR discovery technology, these two platforms allow a full range of cancer therapies to be developed.

Immatics’ pipeline includes T-cell therapy programs based on the proprietary ACTolog ® , ACTengine ® and ACTallo ® approaches, which are developed in collaboration through Immatics US with University of Texas MD Anderson Cancer Center and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT) and several bispecific TCR and antibody molecules.

Operating from Tuebingen, Munich and Houston, the Company has recognized that novel, better and safer targets are the key to developing future cancer immunotherapies and it is Immatics’ mission to deliver the power of T cells to cancer patients.

For regular updates about Immatics, visit www.immatics.com. Contact: Genmab           Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications T: +45 33 44 77 20; M: +45 25 12 62 60; E: rcg@genmab.com This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo ® ; HuMax ® ; DuoBody ® ; DuoBody in combination with the DuoBody logo ® ; HexaBody ® ; HexaBody in combination with the HexaBody logo ® ; and UniBody ® . Arzerra ® is a trademark of Novartis AG or its affiliates. DARZALEX ® is a trademark of Janssen Pharmaceutica NV.

1 Bunk S, et al. Development of highly potent T-cell receptor bispecifics with picomolar activity against tumor-specific HLA ligands [abstract]. In: Proceedings of the 109th Annual Meeting of the American Association for Cancer Research; 2018 Apr 14–18; Chicago, IL. Abstract nr 2789.

Company Announcement no. 20 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V Denmark

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epsium's Inventory Pile Looms Over Weak First Half

Updated Category News Views 85

A warehouse full of bottles is not a balance-sheet fortress when buyers are backing away. Epsium Enterprise’s first-half 2026 report is a rough read: revenue collapsed 51.8% to $1.47 million, gross profit fell to $175,353, and cash slid to $612,761 at June 30. This is not a subtle slowdown. Macau’s premium Chinese-liquor market has been weak on both demand and...

Continue Reading
Tronox Pushes Back on Creditor Restructuring Chatter Firmly

Updated Category News Views 146

A Creditor Rumor Is Not a Restructuring Plan Two creditor groups hiring law firms can make a stock chart look like it stepped on a rake, but it is not the same thing as a debt workout. That distinction is the whole point of Tronox Holdings' November 18 update. A November 17 Wall Street Journal report said two groups of creditors had retained firms described as...

Continue Reading
MERSCO’s Holiday Push Tests Backyard Play Demand in 2026

Updated Category News Views 69

A trampoline sale is not exactly a macroeconomic bellwether, but it does expose a useful little corner of holiday spending: parents buying big, awkward, discretionary stuff that has to earn its space in the yard. MERSCO is joining Amazon’s Black Friday and Cyber Monday window from November 19 through November 30, 2026, with discounts reaching 38% on selected products....

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 98

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 0

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Stardock Fences 7 Targets Messy Windows Desktops Everywhere

Updated Category News Views 137

A cluttered Windows desktop is a tiny tax on attention, and Stardock has spent three decades selling people a way around it. Fences 7, released November 18, 2026, is the latest swing: a Windows 11-focused update that combines cosmetic polish with a genuinely practical privacy feature. This is not grand enterprise software, and nobody should pretend a $10 desktop utility...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 65

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
De Beers Puts Namibia's 176-Carat Owishi on Display

Updated Category News Views 127

A 176-carat natural diamond can still make a room stop breathing, even in a trade battered by arguments over lab-grown supply, luxury spending, and what “rare” ought to mean anymore. De Beers Group, working with Grandview Klein Diamond, has unveiled Namibia’s Owishi natural diamond in Washington, DC. That is the hard fact on the table: a large Namibian stone, a U.S....

Continue Reading
WYBOT's New Robots Push Hands-Free Pool Care in Lyon

Updated Category News Views 77

A pool robot climbing out of the water to dock itself is the sort of demo that makes people stop mid-aisle at a trade show. WYBOT brought precisely that kind of attention-grabber to Piscine Global Lyon 2026, running November 17–20 at Eurexpo Lyon. The company is showing a broader lineup, but the M3 Pro is plainly the headline act: WYBOT calls it the world's first...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 234

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading

Top 5 Most Recently Viewed Articles

Hampton University Museum Reopens to Enrich Cultural Heritage

Updated Category News Views 426

Hampton University Museum Reopens to Enrich Cultural Heritage In an exciting development for cultural enthusiasts, the Hampton University Museum, recognized as the nation's oldest African American museum, has reopened its doors following a comprehensive renovation. This reopening showcases a vibrant collection of exhibits and an enhanced visitor experience. Since its...

Continue Reading
Atlas Systems Recognized for Effective Third-Party Risk Solutions

Updated Category News Views 359

Atlas Systems Achieves Recognition in Gartner's Market Guide Atlas Systems, a prominent leader in third-party risk management solutions, is proud to announce its recognition as a representative vendor in the 2025 Gartner Market Guide for Third-Party Risk Management Technology Solutions. This esteemed recognition highlights the company’s growing influence in transforming...

Continue Reading
Taco Cabana Kicks Off 2025 with Delicious New Menus!

Updated Category News Views 544

Taco Cabana Launches Flavorful New Menu for 2025 The countdown to the new year just became even more appetizing as Taco Cabana is excited to unveil an unforgettable lineup of menu items designed to tantalize taste buds. With offerings that are as bold as they are delicious, Taco Cabana aims to celebrate the new year in style. Beginning January 2, 2025, guests can look...

Continue Reading
Inspecs Group PLC's Recent Trading Activity Overview

Updated Category News Views 239

Essential Insights on Inspecs Group PLC Trading Transactions The financial world is often dynamic and filled with intricate details, especially when it comes to disclosures made by companies. This article focuses on recent dealings related to Inspecs Group PLC and how they fit into the larger context of market activities. Key Information of Recent Dealings As an exempt...

Continue Reading
First Trust Launches ETF to Cater to Clean Energy Demands

Updated Category News Views 165

Introduction to the New ETF from First Trust First Trust Advisors has rolled out the First Trust Indxx Critical Metals ETF (NYSE: FMTL). This marks a significant milestone as it is the 300th ETF from the firm. This innovative fund aims to meet the surging demand from investors for companies focused on the critical metals necessary for clean energy technologies, including...

Continue Reading